Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer

Trial Details

NCT ID

NCT07371104

Phase

PHASE1

Sponsor

Daewoong Pharmaceutical Co. LTD.

Status

RECRUITING

Cancer Type

Ovarian Cancer

Interventions

• DWZ2501 (Olaparib 150mg)
• DWC202510 (Olaparib 150mg)

Locations (sample)

• Seoul, Jongno-gu, South Korea|37.566,126.9784

Key Eligibility Criteria

• 1\. Female subjects aged 19 years or older at the time of obtaining written informed consent.
• 2\. Patients with advanced high-grade ovarian cancer harboring a BRCA mutation. 3. Subjects who meet at least one of the following criteria:
• Subjects who have been maintained on an olaparib dosing regimen of 300 mg (two 150 mg tablets) administered orally twice daily for at least 10 cons…
• Subjects who, in the judgment of the principal investigator require a stable dose of olaparib 300 mg (two 150 mg tablets) administered orally twice…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.